Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MedGenCell
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
PD-1-KO-T, a gene-edited T cell therapy, completed Phase 1 studies for advanced non-small cell lung cancer showing safety evaluation results. Additional programs utilize CRISPR for improved cellular therapies targeting both hematological and solid tumors.
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapyGene therapyCRISPR-based therapy
- Industry
- Biotech
02
Partnerships
Mercer (Beijing) BiotechnologySichuan University (for clinical trials)
Beyond the preview
Go deeper on MedGenCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedGenCell.